REPROCELL Launches FDA-Compliant GMP Manufacturing Platform for Clinical iPSCs
Key Insights
REPROCELL has launched a comprehensive GMP Master Cell Bank manufacturing service for clinical-grade induced pluripotent stem cells from its Maryland facility, offering end-to-end workflow capabilities.
The platform includes the StemRNA (search) Clinical iPSC Seed Clone LLF-34-F3 (search), derived from US donor material and supported by an active FDA Drug Master File.
The integrated service spans donor screening, iPSC manufacturing, gene editing, and GMP banking to accelerate IND submissions for cell therapy developers.
REPROCELL has launched its US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank manufacturing service for human induced pluripotent stem cells (iPSCs), marking a significant advancement in clinical cell therapy manufacturing capabilities. Operating from its Beltsville, Maryland facility, the company now offers a comprehensive end-to-end workflow that spans from clinical seed iPSC production to GMP banking under unified regulatory standards.
Integrated Manufacturing Platform
The new platform integrates several critical manufacturing steps under one coordinated framework, including StemRNA (search)™ clinical seed iPSC manufacturing, StemEdit (search) gene editing services, and GMP Master Cell Bank production. This unified approach enables cell therapy developers to accelerate Investigational New Drug (IND) submissions while reducing regulatory and manufacturing uncertainty.
Central to the platform is the StemRNA (search) Clinical iPSC Seed Clone – LLF-34-F3 (search), derived from US-sourced donor material and supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes, providing ready-to-use clinically validated starting material for commercial applications.
Clinical-Grade Specifications
The StemRNA (search)™ Clinical iPSC Seed Clone – LLF-34-F3 (search) is derived from a healthy O+ female US donor who provided full consent for commercial and therapeutic use. The clone is homozygous at HLA-A (search) and HLA-DPA1 (search) loci, enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA, and PMDA standards while GMP MCB expansion utilizes FDA-compliant processes to ensure traceable, clinically ready starting material.
Key technical capabilities of the platform include donor sourcing and eligibility screening that meets FDA, EMA, and PMDA requirements, footprint-free proprietary RNA reprogramming to generate clinical iPSC seed clones, and genetic integrity assessment using whole-genome sequencing for oncogenic risk evaluation.
Global Regulatory Alignment
For sponsors requiring European regulatory alignment, REPROCELL offers MCB/WCB manufacturing through its partner Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS (search)) under European Medicines Agency oversight, providing global manufacturing flexibility.
The StemEdit (search) clinical gene editing service is engineered for high on-target efficiency with reduced off-target activity and lower predicted immunogenicity, addressing key safety considerations for clinical applications.
Industry Impact
Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc., emphasized the platform's strategic value: "By completing clinical iPSC workflow starting from donor screening, seed iPSC manufacturing, StemEdit (search) gene editing, and GMP cell banking under one coordinated framework, we are delighted to provide cell therapy developers a streamlined path for clinical program development. This integrated platform is designed to accelerate IND/CTA submissions while preserving quality, traceability, and global regulatory alignment."
The development was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (search), highlighting institutional support for advancing clinical cell therapy manufacturing capabilities.
REPROCELL serves academic, biotech, and pharmaceutical organizations seeking reliable, regulatory-ready cell starting materials and services, positioning the company as a comprehensive solution provider for the cell therapy development pipeline from discovery through clinical translation.